EHA 2017

Encouraging data from the RAY trial 3-year follow-up
Simon Rule
6:07
A CRISPR approach to hematological research
Sven Lundberg
2:04
Venetoclax and ibrutinib: the future for treating WM
Steven Treon
4:34
What is the focus of EHA?
Shai Izraeli
5:27
Two is better than one: drug synergy in relapsed/refractory NHL
Paul A. Hamlin
2:34
Key topics on AML at EHA 2017
Oliver Ottmann
0:52
T-cell therapy: successes and unmet needs
David Maloney
2:31
The ideal sequence: treating patients with CLL
Florence Cymbalista
2:00
What are the non-drug-related aspects of patient care?
Claire Harrison
2:19
The potential of momelotinib against myeloproliferative malignancies
Claire Harrison
0:53
NEOD001 in amyloidosis
Morie Gertz
4:16
Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
Paul Cornes
2:24
Are biosimilars as efficacious as their reference drugs?
Paul Cornes
0:52
HARMONY: a collaboration between 51 partners
Lars Bullinger
4:26
Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?
Evangelos Terpos
3:39
Novel agents for myeloma related bone disease
Evangelos Terpos
The content of VJHemOnc is intended for healthcare professionals